Company intelligence
OneChain Immunotherapeutics
Development of CAR-T candidates for the treatment of acute lymphoblastic leukemia and other hematological malignancies.
Biotechnology Research
BARCELONA, ES
21 employees
Founded 2020
4 public signals
About OneChain Immunotherapeutics
OneChain Immunotherapeutics is a spin-off Company from the Josep Carreras Leukemia Research Institute and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.
Verified activity
Signals from OneChain Immunotherapeutics
4 published signals
Research & Knowledge
OneChain Immunotherapeutics presented data showing high levels of specificity and efficacy with the latest lentiviral in vivo CAR-T platform at Advanced Therapies Europe.
Reported by Stefanos Theoharis
Presence & Recognition
OneChain Immunotherapeutics attended the Advanced Therapies Europe conference, engaging in informative panel discussions and catching up with colleagues.
Reported by Stefanos Theoharis
Presence & Recognition
OneChain Immunotherapeutics CEO Stefanos Theoharis will share latest data from the next-generation lentiviral in vivo CAR-T platform at Advanced Therapies Europe 2026 in Barcelona.
Reported by OneChain Immunotherapeutics
Presence & Recognition
OneChain Immunotherapeutics is hosting a talk on Tuesday at 3pm featuring the latest data from the next-generation lentiviral in vivo CAR-T platform.
Reported by Stefanos Theoharis